Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

Molecular Cell

Volumn 3, Issue 5, 1999, Pages 639-648

  Schindler, Thomas ^a   Sicheri, Frank ^a   Pico, Alexander ^b   Gazit, Aviv ^a   Levitzki, Alexander ^c   Kuriyan, John ^d  

^a Laboratory of Molecular Pharmacology   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TYROSINE;

ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; HUMAN; HYDROPHOBICITY; PROTEIN PHOSPHORYLATION;

EID: 0033063429     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80357-3     Document Type: Article

References (46)

1. c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intramolecular autophosphorylation process. Biochemistry 34, 14843-14851.
2. Bolen, J.B., and Brugge, J.S. (1997). Leukocyte protein tyrosine kinases: potential targets for drug dicovery. Annu. Rev. Immunol. 15, 371-404.
3. Brown, M.T., and Cooper, J.A. (1996). Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287, 121-149.
4. Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. (1998). Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921.
5. Carson, M. (1991). Ribbons 2.0. J. Appl. Crystallogr. 24, 958-961.
6. De Bondt, H.L., Rosenblatt, J., Jancarik, J., Jones, H.D., Morgan, D.O., and Kim, S.-H. (1993). Crystal-structure of cyclin-dependent kinase 2. Nature 363, 595-602.
7. Esnouf, R.M. (1997). An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15, 132-134.
8. Ferracini, R., and Brugge, J. (1990). Analysis of mutant forms of the c-src gene product containing a phenylalanine substitution for tyrosine 416. Oncogene Res. 5, 205-219.
9. Fox, T., Coll, J.T., Xie, X., Ford, P.J., Germann, U.A., Porter, M.D., Pazhanisamy, S., Fleming, M.A., Galullo, V., Su, M.S.S., and Wilson, K.P. (1998). A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7, 2249-2255.
10. Gonfloni, S., Williams, J.C., Hattula, K., Weikland, A., Wierenga, R.K., and Superti-Furga, G. (1997). The role of the linker between the SH2 domain and the catalytic domain in the regulation and function of Src. EMBO J. 16, 7262-7271.
11. Hanefeld, U., Rees, C.W., White, A.J.P., and Williams, D.J. (1996). One-pot synthesis of tetra-substituted pyrazoles - proof for regio-chemistry. J. Chem. Soc. Perkin Trans. 1, 1545-1552.
12. Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Brissette, W.H., Weringer, E.J., Pollok, B.A., and Connelly, P.A. (1996). Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 271, 695-701.
13. Hubbard, S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581.
14. Hunter, T. (1987). A tail of two src's: mutatis mutandis. Cell 49, 1-4.
15. Jeffrey, P.D., Russo, A.A., Poylak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N.P. (1995). Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex. Nature 376, 294-295.
16. Johnson, L., Noble, M., and Owen, D. (1996). Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158.
17. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119.
18. c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell 49, 65-73.
19. c-src. Mol. Cell. Biol. 8, 4541-4546.
20. Kuriyan, J., and Cowburn, D. (1997). Modular peptide recognition domains in eukaryotic signaling. Annu. Rev. Biophys. Biomol. Struct. 26, 259-288.
21. LaFevre-Bernt, M., Sicheri, F., Pico, A., Porter, M., Kuriyan, J., and Miller, W.T. (1998). Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue. J. Biol. Chem. 273, 32129-32134.
22. Levitzki, A. (1996). Targeting signal transduction for disease therapy. Curr. Opin. Cell Biol. 8, 239-244.
23. Moarefi, I., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C.H., Kuriyan, J., and Miller, W.T. (1997). Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385, 650-653.
24. Mohammadi, M., Froum, S., Hamby, J.M., Schroeder, M.C., Panek, R.L., Lu, G.H., Eliseenkova, A.V., Green, D., Schlessinger, J., and Hubbard, S.R. (1998). Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904.
25. Narayana, N., Cox, S., Nguyen-huu, X., Ten Eyck, L.F., and Taylor, S.S. (1997). A binary complex of the catalytic subunit of cAMP-dependent protein kinase and adenosine further defines conformational flexibility. Structure 5, 921-935.
26. Navaza, J. (1994). Amore: an automated package for molecular replacement. Acta Crystallogr. D 50, 157-163.
27. Nicholls, A., Sharp, K.A., and Honig, B. (1991). Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281-296.
28. Otwinowski, Z., and Minor, W. (1997). Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326.
29. Pawson, T. (1995). Protein modules and signaling networks. Nature 373, 573-580.
30. c-src. Cell 49, 75-82.
31. Read, R.J. (1986). Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr. A 42, 140-149.
32. Sicheri, F., and Kuriyan, J. (1997). Structures of Src-family tyrosine kinases. Curr. Opin. Struct. Biol. 7, 777-785.
33. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609.
34. v-src. Cell 32, 891-901.
35. Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R.J., et al. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767-778.
36. Southwick, P.L., and Dhawan, B. (1975). Preparation of 4,6-diaminopyrazolo[3,4-d]pyrimidines with variations in substitutions at the 1- and 3-positions. J. Hetero. Chem. 12, 1199-1205.
37. Superti-Furga, G., Fumagalli, S., Koegl, M., Courtneidge, S.A., and Draetta, G. (1993). Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 12, 2625-2634.
38. Thomas, A.M., and Brugge, J.S. (1997). Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Biol. 13, 513-609.
39. Trumpp-Kallmeyer, S., Rubin, J.R., Humblet, C., Hamby, J.M., and Showalter, H.D.H. (1998). Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J. Med. Chem. 41, 1752-1763.
40. Wang, Z., Canagarajah, B.J., Boehm, J.C., Kassisa, S., Cobb, M.H., Young, P.R., Abdel-Meguid, S., Adams, J.L., and Goldsmith, E.J. (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128.
41. Williams, J.C., Weijland, A., Gonfloni, S., Thompson, A., Courtneidge, S.A., Superti-Furga, G., and Wierenga, R.K. (1997). The 2.35 Å crystal structure of the inactivated form of chicken Src: a dynamic model with multiple regulatory interactions. J. Mol. Biol. 274, 757-775.
42. Wilson, K.P., McCaffrey, P.G., Hsiao, K., Pazhanisamy, S., Galullo, V., Bemis, G.W., Fitzgibbon, M.J., Caron, P.R., Murcko, M.A., and Su, M .S.S. (1997). The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 4, 423-431.
43. Xu, W., Harrison, S.C., and Eck, M.J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602.
44. Xu, W., Doshi, A., Lei, M., Eck, M.J., and Harrison, S.C. (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3, this issue, 629-638.
45. Yamaguchi, H., and Hendrickson, W.A. (1996). Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384, 484-489.
46. Zheng, J., Trafny, E.A., Knighton, D.R., Xuong, N.-H., Taylor, S.S., Ten Eyck, L.F., and Sowadski, J.M. (1993). 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. D 49, 362-365.